Straits Times Index
3,314.05 +0.57 (+0.02%) S&P 500
5,313.68 +10.41 (+0.20%) Dow
39,899.46 -104.13 (-0.26%) Nasdaq
16,788.08 +102.12 (+0.61%) Bitcoin USD
68,271.35 +1,509.87 (+2.26%) CMC Crypto 200
1,391.04 +36.63 (+2.70%)
The fight against COVID19
23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
14 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 152.3 | -1.10 | -0.72% | 1:48 pm GMT-4 | 2.90M | 7.42M | 366.54B |
| ABBV | AbbVie Inc. | 165.188 | -1.23 | -0.74% | 1:47 pm GMT-4 | 1.19M | 5.62M | 291.70B |
| PFE | Pfizer Inc. | 28.6899 | +0.05 | +0.17% | 1:48 pm GMT-4 | 13.39M | 42.61M | 162.57B |
| SNY | Sanofi | 48.56 | -0.11 | -0.23% | 1:46 pm GMT-4 | 680.56k | 1.98M | 122.52B |
| REGN | Regeneron Pharmaceuticals, Inc. | 983.535 | +1.24 | +0.13% | 1:44 pm GMT-4 | 117.90k | 456.01k | 108.37B |
| GSK | GSK plc | 45.175 | +0.19 | +0.43% | 1:48 pm GMT-4 | 929.97k | 3.14M | 94.21B |
| GILD | Gilead Sciences, Inc. | 67.9 | +0.18 | +0.27% | 1:48 pm GMT-4 | 1.35M | 6.95M | 84.59B |
| MRNA | Moderna, Inc. | 141.6689 | +8.77 | +6.60% | 1:48 pm GMT-4 | 2.89M | 3.83M | 54.29B |
| TAK | Takeda Pharmaceutical Company Limited | 13.285 | +0.06 | +0.49% | 1:45 pm GMT-4 | 371.25k | 1.65M | 41.91B |
| BNTX | BioNTech SE | 92.32 | +1.71 | +1.89% | 1:45 pm GMT-4 | 179.61k | 593.47k | 22.25B |
| NVAX | Novavax, Inc. | 14.26 | +1.25 | +9.61% | 1:48 pm GMT-4 | 9.31M | 12.93M | 2.10B |
| VIR | Vir Biotechnology, Inc. | 9.86 | +0.13 | +1.34% | 1:47 pm GMT-4 | 317.30k | 982.48k | 1.34B |
| INO | Inovio Pharmaceuticals, Inc. | 11.165 | -0.84 | -6.96% | 1:48 pm GMT-4 | 207.68k | 441.90k | 289.29M |
BenzingaGilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Saturday, Gilead Sciences Inc (NASDAQ:GILD), following the recent acquisition of CymaBay Therapeutics Inc, announced interim results from the ongoing ASSURE study. The ASSURE study is an open-label study to evaluate the long-term safety and tolerability of seladelpar in people with primary biliary cholangitis (PBC) who have already participated in other PBC clinical trials of seladelpar. The study is currently enrolling up to 500 people. Also Read: Gilead’s Aggressive Push Beyond HIV Treatments
Motley Fool1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Revenue growth during what should be a disastrous patent cliff is encouraging.
ZacksAstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
